Strategic partnerships ContraFect focuses on direct lytic agents including lysins and amurin peptides to treat antibiotic-resistant infections, presenting sales opportunities with government grant programs, defense and biodefense channels, and collaborations with research institutions seeking novel antimicrobials.

Clinical leadership Lead candidate exebacase has FDA Breakthrough Therapy designation and is in pivotal Phase 3 for MRSA bloodstream infections, signaling a pathway for hospital systems and ID/antibiotic stewardship programs to adopt expanded-use strategies and reimbursement planning.

Pivotal trials Active Phase 3 study status creates near-term outreach touchpoints with trial sites, cooperative groups, and hospital networks managing serious infections, offering investigator-initiated studies, sample access, and potential purchasing discussions tied to trial progress.

Public funding Significant government funding and BARDA support indicate strong opportunities to engage with public sector buyers, grant-funded collaboration opportunities, and potential co-development or procurement pathways aligned with national biodefense and pandemic preparedness priorities.

Market potential Addressing antibiotic-resistant pathogens such as MRSA and Pseudomonas aeruginosa positions ContraFect to target high-impact clinical segments, including intensive care units, prosthetic joint infection programs, and biofilm-associated infections, where DLAs may complement standard of care.